Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

Next Previous
X
Search
Trial Profile

My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Cobimetinib (Primary) ; Erlotinib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Vemurafenib (Primary) ; Vismodegib (Primary)
  • Indications Adenocarcinoma; Adrenocortical carcinoma; Biliary cancer; Bladder cancer; Breast cancer; Carcinoma; Cervical cancer; CNS cancer; Colon cancer; Colorectal cancer; Fallopian tube cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Leiomyosarcoma; Liver cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Salivary gland cancer; Sarcoma; Skin cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Thyroid cancer; Tumours; Urogenital cancer; Uterine cancer
  • Focus Therapeutic Use
  • Acronyms Mypathway
  • Sponsors Genentech

    • Most Recent Events

    • 04 Oct 2023 Results (At data cutoff March 2022, n=346 ) assessing efficacy of Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors published in the Journal of Clinical Oncology
    • 06 Jun 2023 Status changed from active, no longer recruiting to completed.
    • 17 Mar 2023 Planned End Date changed from 29 Sep 2023 to 12 May 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top